Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
COVID-19: India restricts drug exports amid rising prices of essential bulk drugs; FDA announces first drug shortage
Now that it has been
established that the novel coronavirus is going to globally impact the drug
s
Mid-2017 Recap of FDA Warning Letters, Import Alerts & EU Non-Compliances
Last year, data
integrity was a hot topic of discussion in the pharmaceutical industry.
According t
FDA proposes delayed track and trace rollout; GSK forays into artificial intelligence-aided drug research
This week, Phispers brings you news on an apex court ruling in Canada that overhauls its patent law
Compliance Wrap: Heparin quality concerns re-emerge in China, more trouble at Sun Pharma & Wockhardt
PharmaCompass looks at recent compliance concerns highlighted by the US FDA at drug manufacturers li
If deleting electronic records is okay, then it must be okay to rip out pages from lab notebooks
This week, Speak Pharma interviews Mark S.
Paxton, the Chief Executive Officer of Rx-360, a non-prof
Data integrity has no relationship with product quality
Peter J. Werth, President and Chief Executive Officer, ChemWerth, a US-headquartered full-service ge
Phispers: Another Heparin scandal in China, GSK may have a new CEO, Female libido pill problems
Pharmaceutical Whispers (Phispers) this week cover another major heparin scandal emanating from
Counterfeit drugs: Toyota’s highest ranking female employee arrested; it’s time to understand!
Yesterday, on July 1, 2015, the Drug Supply
Chain Security Act (or Drug Quality
and Security Act) b
